Publisher: Adis International
ISSN: 1173-5503
Source: PharmacoEconomics and Outcomes News, Vol.1, Iss.463, 2004-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Potential for high clinical, cost burden with MRSA
Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. :
MRSA financial burden high, but rapid screening could help
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 580, 2009-01 ,pp. :
C. difficile-associated diarrhoea imposes high cost burden in the US
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 358, 2002-01 ,pp. :
Economic burden of MRSA-related NP substantial
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 668, 2012-01 ,pp. :
Oral linezolid cost saving in MRSA-related infections
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 482, 2005-01 ,pp. :